Please login to order a test.
Sirolimus, Whole Blood
Monitor immunosuppressive therapy following organ transplant
This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.
Liquid chromatography/tandem mass spectrometry (LC/MS-MS)
Sirolimus may be administered in conjunction with cyclosporine (CsA) and corticosteroids to reduce or prevent host graft rejection. Using this therapy, peak concentrations are achieved in one to two hours. The mean terminal elimination half-life is 62 hours.1 Drug-drug interactions, including CsA, may alter the pharmacokinetics of sirolimus, making therapeutic drug monitoring appropriate.
Lavender-top (EDTA) tube
Trough: 30 minutes to one hour before the next oral dose
Causes for Rejection
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|716712||Sirolimus (Rapamune), Blood||29247-4||716713||Sirolimus, Blood||ng/mL||29247-4|